Vietnam encourages Chinese enterprises to invest in local agribusiness

Sharing insights on Vietnam’s livestock and veterinary sector, Deputy Minister Tien emphasized that the industry is experiencing strong growth with remarkable achievements. This year, Vietnam is expected to produce around 8.8 million tons of meat, 22 billion eggs, and 1.3 million tons of milk. The national pig herd remains stable at around 31 million head, while the population of grazing livestock stands at nearly 10 million, of which cattle, goats, and sheep account for about 2.8 million. At the same time, the fisheries sector continues to hold a vital role, producing some 5.9 million tons of farmed seafood annually. Within that figure, marine aquaculture alone contributes 1 million tons, helping to generate export revenues of roughly USD 12 billion.

Alongside the establishment of numerous research facilities for veterinary medicine and vaccine development, Vietnam welcomes international cooperation to further strengthen the livestock sector, ensure food security, and promote sustainable development.

Mr. Zhang Chongyu, Chairman of the Board of Directors of Jinyu Bio-Technology Joint Stock Company, emphasized the vital role of veterinary vaccines, especially at a time when African swine fever continues to evolve in a complicated manner. “Only when our animals are healthy and raised in a safe environment can we effectively protect consumers,” he affirmed. "Through this visit, we hoped Jinyu’s latest research outcomes could soon be introduced into Vietnam, thereby helping the country strengthen disease control and limit the spread of dangerous pathogens."

Regarding vaccines against African swine fever, Mr. Zhang Chongyu explained that Jinyu is diversifying its research pathways to create more effective and sustainable solutions. These include the development of traditional vaccines, subunit vaccines, advanced mRNA-based vaccines, and cutting-edge digital vaccine technologies.

According to him, such a broad research portfolio not only demonstrates the company’s long-term vision but also opens new opportunities for international cooperation, technology transfer, and the eventual commercialization of vaccines that could significantly contribute to Vietnam’s livestock industry.

The first generation of vaccines consists of whole-virus or whole-bacterium vaccines, including both inactivated and live-attenuated types. The second generation is recombinant protein subunit vaccines, one of which was approved for clinical trials in April 2025. By October this year, the company plans to conduct trials on 130,000 pigs across three provinces in China. Notably, the third generation, mRNA vaccines, based on nucleic acid therapy, are expected to offer broad potential for application against multiple types of diseases.

“In the next five years, the company aims to develop an integrated biotechnology strategy that applies digital technologies to accelerate vaccine research and deliver comprehensive solutions for the livestock industry. At the same time, we hope to foster scientific and technological cooperation and help strengthen the research capacity of Vietnamese scientists,” Mr. Zhang stated.

Recognizing Jinyu's strong development potential, Deputy Minister Tien expressed his support for Chinese enterprises investing in Vietnam. To facilitate this process, he proposed that the International Cooperation Department conduct more in-depth discussions with the company and establish connections with the Vietnam Veterinary Association, thereby creating a solid foundation for enterprises from both sides to advance practical and mutually beneficial cooperation.

“I encourage enterprises to thoroughly study Vietnam’s policies and legal framework before making investment decisions. At the same time, Vietnam is committed to creating favorable conditions and providing support in case of challenges or obstacles during implementation,” Deputy Minister Tien affirmed.

Jinyu Bio-Technology Joint Stock Company is one of China’s leading enterprises in the field of veterinary vaccines and pharmaceuticals. Established in 1993, the company is headquartered in Hohhot, Inner Mongolia, and is listed on the Shanghai Stock Exchange.

In addition to developing vaccines for livestock, poultry, and companion animals, the company has established a number of state-of-the-art research centers, including a P3-level biosafety laboratory dedicated to studying highly dangerous pathogens. In recent years, Jinyu has intensified its focus on next-generation vaccine technologies, such as subunit vaccines and mRNA vaccines, while also expanding cooperation with research institutes and biotechnology companies both within China and internationally.